Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07497087 · ClinicalTrials.gov registry record · Phase 3
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Not yet
- Registry status
- Phase 3
- Development phase
- 448
- Enrollment target
NCT07497087 is a Phase 3 study that has not yet begun recruiting, run by Boehringer Ingelheim. The registered enrollment target is 448 participants.
The verdict
NCT07497087, a Phase 3 study, has not yet begun recruiting, sponsored by Boehringer Ingelheim.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 448 participants
- Enrollment target
Study Summary
Nerandomilast is being developed to help people with systemic sclerosis by potentially improving symptoms and slowing disease progression. This study is open to adults who are at least 18 years old and have systemic sclerosis (SSc). People can join the study if they have limited or diffuse cutaneous SSc with disease onset within 7 years of the first non-Raynaud's symptom. The purpose of this study is to find out whether a medicine called nerandomilast helps people with systemic sclerosis. This study also aims to find out how well nerandomilast is tolerated in people with systemic sclerosis. Participants are put into 2 groups randomly, which means by chance. One group takes nerandomilast tablets and the other group takes placebo tablets. Placebo tablets look like nerandomilast tablets but do not contain any medicine. Participants take the tablets twice a day. Participants are in the study for 1 to about 4 years. During this time, they visit the study site regularly and get phone calls from the site staff. During study visits participants regularly have blood samples taken and doctors check changes in skin thickening, lung function, and internal organs, overall health and the safety and tolerability of study treatment in people with SSc. The results are compared between the groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.
Interventions
- DRUG Placebo matching nerandomilast formulation 1
- DRUG Placebo matching nerandomilast formulation 2
- DRUG Nerandomilast formulation 1
- DRUG Nerandomilast formulation 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 448 participants |
| Start Date | 2026-07-10 |
| Est. Completion | 2030-03-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07497087
The ClinicalTrials.gov registry entry for NCT07497087 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 448 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo matching nerandomilast formulation 1 is the first listed.
NCT07497087 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07497087 about?
NCT07497087 is a clinical study titled "A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis". Nerandomilast is being developed to help people with systemic sclerosis by potentially improving symptoms and slowing disease progression. This study is open to adults who are at least 18 years old and have systemic sclerosis (SSc). People can join the study if they have limited or diffuse cutaneous...
What is the current status of trial NCT07497087?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 448 participants. The study started on 2026-07-10. Estimated completion is 2030-03-17.
What interventions are being tested in trial NCT07497087?
The interventions under investigation include: Placebo matching nerandomilast formulation 1 (DRUG), Placebo matching nerandomilast formulation 2 (DRUG), Nerandomilast formulation 1 (DRUG), Nerandomilast formulation 2 (DRUG).
Who is sponsoring clinical trial NCT07497087?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.